Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KCNA3 | P22001 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3606190 | 1.00 | MEN1 (0.46) | MEN1KMT2AKCNA3ALDH1A1KDM4E | |
| SCHEMBL14221420 | 0.92 | MEN1 (0.41) | MEN1KMT2AALDH1A1KDM4EPOLB | |
| SCHEMBL13442788 | 0.86 | KCNA3 (0.55) | MEN1KMT2AKCNA3ALDH1A1KDM4E | |
| SCHEMBL3614647 | 0.85 | MEN1 (0.48) | MEN1KMT2AKCNA3ALDH1A1KDM4E | |
| SCHEMBL3609717 | 0.84 | MEN1 (0.43) | MEN1KMT2AKCNA3ALDH1A1KDM4E | |
| SCHEMBL3600871 | 0.84 | MEN1 (0.45) | MEN1KMT2AKCNA3ALDH1A1KDM4E | |
| SCHEMBL3600879 | 0.84 | MEN1 (0.45) | MEN1KMT2AKCNA3ALDH1A1KDM4E | |
| SCHEMBL3607871 | 0.84 | MEN1 (0.45) | MEN1KMT2AKCNA3ALDH1A1KDM4E | |
| SCHEMBL13442823 | 0.83 | MEN1 (0.44) | MEN1KMT2AKCNA3ALDH1A1KDM4E | |
| SCHEMBL3602360 | 0.83 | MEN1 (0.46) | MEN1KMT2AKCNA3ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309545-B2 | Benzofuran potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2012-11-13 | — | — | US | disclosed |
| US-8309545-B2 | Benzofuran potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2012-11-13 | — | — | US | disclosed |
| US-20100087430-A1 | NOVEL BENZOFURAN POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2010-04-08 | — | — | US | disclosed |
| US-20100087430-A1 | NOVEL BENZOFURAN POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087430-A1 | NOVEL BENZOFURAN POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | KCNA3, KCNB1, KCNK3 | MEN1 3359/4885KMT2A 847/4885KCNA3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.